What is the appropriate age range to initiate aripiprazole (Abilify), and can it be used to treat premenstrual dysphoric disorder (PMDD)?

Age Range for Starting Abilify and Use in PMDD

Abilify (aripiprazole) is FDA-approved for use starting at age 6 years for specific indications (irritability associated with autistic disorder and Tourette's disorder), age 10 years for bipolar I disorder, and age 13 years for schizophrenia, but it is NOT approved or recommended for treating premenstrual dysphoric disorder (PMDD). 1

FDA-Approved Age Ranges for Abilify

The specific age thresholds for aripiprazole initiation vary by indication 1:

• Age 6 years and older: Irritability associated with autistic disorder and Tourette's disorder 1
• Age 10 years and older: Bipolar I disorder (manic or mixed episodes) 1
• Age 13 years and older: Schizophrenia 1
• Adults: Major depressive disorder (as adjunctive treatment with antidepressants) 1

Important caveat: While aripiprazole has FDA approval for acute mania in adults, the 2007 guidelines note that aripiprazole was only approved for adult acute mania at that time, not specifically for pediatric bipolar disorder 2. The pediatric approvals came later.

Safety Considerations by Age and Weight

Research suggests significant age and weight-related safety concerns 3:

• Children under 8.6 years old: All three children in this age group developed adverse events (increased lability and aggression) before achieving clinical efficacy 3
• Children under 34 kg: All four children in this weight category experienced adverse events 3
• Children over 11 years and over 58 kg: Had a 56% success rate with better tolerability 3

Co-administration with sedative medications (particularly guanfacine or clonidine) significantly increases the risk of adverse events in pediatric patients 3. The FDA label confirms that pediatric patients aged 6-18 years experienced higher rates of adverse effects than adults, particularly somnolence (24% vs 11% in adults) 1.

Abilify for PMDD: Not Recommended

Aripiprazole has no established role in treating PMDD and should not be used for this indication. The evidence-based treatments for PMDD are entirely different:

First-Line Treatment for PMDD

Selective serotonin reuptake inhibitors (SSRIs) are the established first-line treatment for PMDD 4, 5, 6:

• Sertraline 50-150 mg/day 7
• Fluoxetine 10-20 mg/day 7
• Escitalopram 10-20 mg/day 7
• Paroxetine 12.5-25 mg/day 7

SSRIs can be administered either continuously or during the luteal phase only, with continuous administration showing superior efficacy (SMD -0.69 vs -0.39 for luteal phase) 6.

Second-Line Treatment for PMDD

Combined oral contraceptives containing drospirenone (specifically the 24/4 regimen with 3 mg drospirenone and 20 mcg ethinyl estradiol) are effective second-line options 4, 8, 5. This formulation showed particularly positive outcomes for both physical and emotional symptoms 8.

Additional Evidence-Based Options

• Calcium supplementation: Has demonstrated consistent therapeutic benefit 5
• Cognitive-behavioral therapy (CBT): Shows positive results in reducing functional impairment, depressed mood, anxiety, and mood swings 7, 6

Clinical Pitfalls to Avoid

1. Do not prescribe aripiprazole for PMDD - there is no evidence supporting this use, and it would expose patients to unnecessary risks including metabolic effects, extrapyramidal symptoms, and weight gain 9

2. In pediatric populations requiring aripiprazole for approved indications: Avoid combining with alpha-2 agonists (clonidine/guanfacine) when possible, as this combination increases adverse event risk 3

3. For PMDD treatment: Do not use antipsychotics when SSRIs and hormonal contraceptives are the evidence-based options with proven efficacy 4, 8, 5, 6

4. Monitor closely for suicidality: The FDA requires a boxed warning for all antidepressants (including SSRIs used for PMDD) regarding increased suicidal thoughts in children, adolescents, and young adults 1